Michael P. Schroeder

Michael P. Schroeder

Auto-generated profile, based on publicly available information

Michael P. Schroeder

Research Program on Biomedical Informatics (GRIB), IMIM Hospital del Mar Medical, Research Institute and Pompeu Fabra University, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2013 in Nature Methods
Verified
Journal Article
Open access
PDF file
AGAbel Gonzalez-Perez
Abel Gonzalez-Perez
CPChristian Perez-Llamas
Christian Perez-Llamas
JDJordi Deu-Pons
Jordi Deu-Pons
DTDavid Tamborero
David Tamborero
MSMichael P Schroeder
Michael P Schroeder
NLNuria Lopez-Bigas
Nuria Lopez-Bigas
IntOGen-mutations is a discovery tool for cancer researchers to find driver mutations in genes and pathways. The IntOGen-mutations platform ( http://www.intogen.org/mutations/ ) summarizes somatic mutations, genes and pathways involved in tumorigenesis. It identifies and visualizes cancer drivers, analyzing 4,623 exomes from 13 cancer sites. It provides support to cancer researchers, aids the identification of drivers across tumor cohorts and helps rank mutations for better clinical decision-making.

28 March 2018 in Genome Medicine
Verified
Journal Article
Open access
PDF file
DTDavid Tamborero
David Tamborero
CRCarlota Rubio-Perez
Carlota Rubio-Perez
JDJordi Deu-Pons
Jordi Deu-Pons
MSMichael P. Schroeder
Michael P. Schroeder
AVAna Vivancos
Ana Vivancos
NLNuria Lopez-Bigas
Nuria Lopez-Bigas
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. The results are organized in different levels of evidence according to current knowledge, which we envision can support a broad range of oncology use cases. The resource is publicly available at http://www.cancergenomeinterpreter.org .

1 March 2015 in Cancer Cell
Verified
Journal Article
Closed access
CRCarlota Rubio-Perez
Carlota Rubio-Perez
DTDavid Tamborero
David Tamborero
MSMichael P. Schroeder
Michael P. Schroeder
AAAlbert A. Antolín
Albert A. Antolín
JDJordi Deu-Pons
Jordi Deu-Pons
NLNuria Lopez-Bigas
Nuria Lopez-Bigas

11 November 2016 in Leukemia
Verified
Journal Article
Closed access
EHE K von der Heide
E K von der Heide
MNM Neumann
M Neumann
SVS Vosberg
S Vosberg
AJA R James
A R James
MSM P Schroeder
M P Schroeder
CBC D Baldus
C D Baldus

31 January 2013 in Genome Medicine
Verified
Journal Article
Open access
PDF file
MSMichael P Schroeder
Michael P Schroeder
AGAbel Gonzalez-Perez
Abel Gonzalez-Perez
NLNuria Lopez-Bigas
Nuria Lopez-Bigas
Cancer genomics projects employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Examples include projects carried out by the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). A crucial step in the extraction of knowledge from the data is the exploration by experts of the different alterations, as well as the multiple relationships between them. To that end, the use of intuitive visualization tools that can integrate different types of alterations with clinical data is essential to the field of cancer genomics. Here, we review effective and common visualization techniques for exploring oncogenomics data and discuss a selection of tools that allow researchers to effectively visualize multidimensional oncogenomics datasets. The review covers visualization methods employed by tools such as Circos, Gitools, the Integrative Genomics Viewer, Cytoscape, Savant Genome Browser, StratomeX and platforms such as cBio Cancer Genomics Portal, IntOGen, the UCSC Cancer Genomics Browser, the Regulome Explorer and the Cancer Genome Workbench.

5 June 2017 in Oncogene
Verified
Journal Article
Open access
EVE Vidal
E Vidal
SSS Sayols
S Sayols
SMS Moran
S Moran
AGA Guillaumet-Adkins
A Guillaumet-Adkins
MSM P Schroeder
M P Schroeder
MEManel Esteller
Manel Esteller
Although single base-pair resolution DNA methylation landscapes for embryonic and different somatic cell types provided important insights into epigenetic dynamics and cell-type specificity, such comprehensive profiling is incomplete across human cancer types. This prompted us to perform genome-wide DNA methylation profiling of 22 samples derived from normal tissues and associated neoplasms, including primary tumors and cancer cell lines. Unlike their invariant normal counterparts, cancer samples exhibited highly variable CpG methylation levels in a large proportion of the genome, involving progressive changes during tumor evolution. The whole-genome sequencing results from selected samples were replicated in a large cohort of 1112 primary tumors of various cancer types using genome-scale DNA methylation analysis. Specifically, we determined DNA hypermethylation of promoters and enhancers regulating tumor-suppressor genes, with potential cancer-driving effects. DNA hypermethylation events showed evidence of positive selection, mutual exclusivity and tissue specificity, suggesting their active participation in neoplastic transformation. Our data highlight the extensive changes in DNA methylation that occur in cancer onset, progression and dissemination.